Details

Autor(en) / Beteiligte

• Costedoat-Chalumeau, Nathalie
• Galicier, Lionel
• Aumaître, Olivier
• Francès, Camille
• Le Guern, Véronique
• Lioté, Frédéric
• Smail, Amar
• Limal, Nicolas
• Perard, Laurent
• Desmurs-Clavel, Hélène
• Boutin, Du Le Thi Huong
• Asli, Bouchra
• Kahn, Jean-Emmanuel
• Pourrat, Jacques
• Sailler, Laurent
• Ackermann, Félix
• Papo, Thomas
• Sacré, Karim
• Fain, Olivier
• Stirnemann, Jerome
• Cacoub, Patrice
• Jallouli, Moez
• Leroux, Gaelle
• Cohen-Bittan, Judith
• Tanguy, Marie-Laure
• Hulot, Jean-Sébastien
• Lechat, Philippe
• Musset, Lucile
• Amoura, Zahir
• Piette, Jean-Charles

Titel

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

Ist Teil von

• Annals of the rheumatic diseases, 2013-11, Vol.72 (11), p.1786-1792

Ort / Verlag

England: BMJ Publishing Group Ltd and European League Against Rheumatism

Erscheinungsjahr

2013

Quelle

BMJ Journals Archiv - DFG Nationallizenzen

Beschreibungen/Notizen

• Introduction Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares. Patients and methods [HCQ] was measured in 573 patients with SLE (stable disease and SELENA-SLEDAI≤12) treated with HCQ for at least 6 months. Patients with [HCQ] from 100 to 750 ng/ml were randomised to one of two treatment groups: no daily dose change (group 1) or increased HCQ dose to achieve the target [HCQ] (group 2). The primary end point was the number of patients with flares during 7 months of follow-up. Results Overall, mean [HCQ] was 918±451 ng/ml. Active SLE was less prevalent in patients with higher [HCQ]. A total of 171 patients were randomised and followed for 7 months. SLE flare rates were similar in the two groups (25% in group 1 vs 27.6% in group 2; p=0.7), but a significant spontaneous increase in [HCQ] in both groups between inclusion and randomisation strongly suggested improved treatment adherence. Patients at the therapeutic target throughout follow-up tended to have fewer flares than those with low [HCQ] (20.5% vs 35.1%, p=0.12). Conclusions Although low [HCQ] is associated with higher SLE activity, adapting the HCQ dose did not reduce SLE flares over a 7-month follow-up. ClinicalTrials.gov NCT00413361